Mesenchymal stem cells: current clinical progress in ARDS and COVID-19

Acute respiratory distress syndrome (ARDS) develops rapidly and has a high mortality rate. Survivors usually have low quality of life. Current clinical management strategies are respiratory support and restricted fluid input, and there is no suggested pharmacological treatment. Mesenchymal stromal c...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiao, Kun, Hou, Fei, Huang, Xiuyu, Li, Binbin, Qian, Zhi Rong, Xie, Lixin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373844/
https://www.ncbi.nlm.nih.gov/pubmed/32698898
http://dx.doi.org/10.1186/s13287-020-01804-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373844/
https://www.ncbi.nlm.nih.gov/pubmed/32698898
http://dx.doi.org/10.1186/s13287-020-01804-6

Ejemplares similares